drospirenone/ethinyl estradiol/levomefolate (Rx)

Brand and Other Names:Beyaz, Safyral, more...Tydemy

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

drospirenone/ethinyl estradiol/levomefolate

tablet

  • 3mg/0.02mg/0.451mg (Beyaz)
  • 3mg/0.03mg/0.451mg (Safyral, Tydemy)

Contraception

Safyral, Tydemy

  • 1 active tablet (3 mg drospirenone/0.03 mg EE) PO qDay for 21 days, THEN 1 inert tablet PO qDay for 7 days

Beyaz

  • 1 active tablet (3 mg drospirenone/0.02 mg EE) PO qDay for 24 days, THEN 1 inert tablet PO qDay for 4 days

Moderate Acne Vulgaris

Beyaz

  • Indicated for moderate acne in women, but only if oral contraceptive is chosen as method of birth control
  • 1 active tablet (3 mg drospirenone/0.02 mg EE) PO qDay for 24 days, THEN 1 inert tablet PO qDay for 4 days

Premenstrual Dysphoric Disorder

Beyaz

  • Indicated for symptoms of premenstrual dysphoric disorder (PMDD), but only if oral contraceptive is chosen as method of birth control
  • 1 active tablet (3 mg drospirenone/0.02 mg EE) PO qDay for 24 days, THEN 1 inert tablet PO qDay for 4 days

Dosage Modifications

Renal impairment: Contraindicated

Hepatic impairment: Contraindicated

Dosing Considerations

Women should be advised to use additional nonhormonal contraception during the first 7 days of therapy

Administer tablets in the order directed on the blister pack calendar at the same time each day

Increased risk for venous thromboembolism (VTE) with combined hormonal contraceptives following delivery; risk declines rapidly after 21 days but does not return to normal until 42 days after delivery

CDC guidelines recommend waiting 21-42 days to initiate therapy in postpartum women without additional VTE risks (MMWR July 7, 2011)

Postpartum women who do not breastfeed or after a second trimester abortion: Wait ≥4 weeks to initiate therapy

Postpartum women who have had a caesarean section birth: Wait ≥6 weeks to initiate therapy

Women with other risk factors for VTE in addition to postpartum: Do not use combined hormonal contraceptives

Dosage Forms & Strengths

drospirenone/ethinyl estradiol/levomefolate

tablet

  • 3mg/0.02mg/0.451mg (Beyaz)
  • 3mg/0.03mg/0.451mg (Safyral, Tydemy)

Contraception

<14 years

  • Safety and efficacy not established

≥14 years

  • Safyral, Tydemy
    • 1 active tablet (3 mg drospirenone/0.03 mg EE) PO qDay for 21 days, THEN 1 inert tablet PO qDay for 7 days
  • Beyaz
    • 1 active tablet (3 mg drospirenone/0.02 mg EE) PO qDay for 24 days, THEN 1 inert tablet PO qDay for 4 days

Moderate Acne Vulgaris

Moderate acne in females ≥14 years, but only if oral contraceptive is chosen as method of birth control

<14 years

  • Safety and efficacy not established

≥14 years

  • Beyaz

    • Indicated for moderate acne in women, but only if oral contraceptive is chosen as method of birth control
    • 1 active tablet (3 mg drospirenone/0.02 mg EE) PO qDay for 24 days, THEN 1 inert tablet PO qDay for 4 days
Next:

Interactions

Interaction Checker

and drospirenone/ethinyl estradiol/levomefolate

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Due to system maintenance, the drug interactions feature you are attempting to access is temporarily unavailable. Please try again later.
            Previous
            Next:

            Adverse Effects

            >10%

            Premenstrual syndrome (13.2%)

            Migraine/headache (10.7%)

            1-10%

            Breast pain/discomfort/tenderness (8.3%)

            Menstrual irregularities (4.7%)

            Nausea/vomiting (4.5%)

            Abdominal pain/discomfort/tenderness (2.3%)

            Mood changes, including affect lability, depression, alteration of mood, mood swings, and irritability (2.3%)

            Frequency Not Defined

            Irregular uterine bleeding

            Venous/arterial thromboembolic events, including DVT, PE, stroke, MI, intracardiac thrombosis, sagittal sinus thrombosis, intracranial venous sinus thrombosis, retinal vein thrombosis

            Hypertension

            Hypersensitivity

            Hyperkalemia

            Chloasma

            Gallbladder disease

            Toxic skin eruption

            Uterine leiomyoma

            Previous
            Next:

            Warnings

            Black Box Warnings

            Cigarette smoking and risk of cardiovascular disease

            • Women >35 years who smoke should not use oral contraceptives
            • Cigarette smoking increases risk of serious cardiovascular adverse effects from combination oral contraceptive use
            • This risk increases with age (>35 yr) and with heavy smoking (15 or more cigarettes/day)
            • Advise women taking oral contraceptives not to smoke

            Contraindications

            Documented hypersensitivity

            Active/history of breast cancer or estrogen- or progestin-sensitive caner

            Active/history of arterial thromboembolic disease (stroke, MI), thrombophlebitis, DVT/PE, thrombogenic valvular disease

            Uncontrolled hypertension

            Diabetes mellitus with vascular involvement

            History of migraine with aura

            Undiagnosed abnormal uterine bleeding

            Benign or malignant liver tumors, hepatic impairment or development of jaundice with prior oral contraceptive use

            Pregnancy

            Renal impairment

            Adrenal insufficiency

            Receiving hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir

            Cautions

            Due to increased risk of hyperkalemia, monitor serum potassium during first month if coadministered with potassium-elevating/sparing drugs (eg, spironolactone); consider monitoring serum potassium concentration in high-risk patients who take a strong CYP3A4 inhibitor long-term and concomitantly; strong CYP3A4 inhibitors include azole antifungals (e.g. ketoconazole, itraconazole, voriconazole), HIV/HCV protease inhibitors (e.g., indinavir, boceprevir), and clarithromycin

            Family history of breast cancer and or DVT/PE

            Current/history of depression, endometriosis, DM, HTN, bone mineral density changes, renal/hepatic impairment, bone metabolic disease, SLE

            Conditions exacerbated by fluid retention (eg, migraine, asthma, epilepsy)

            Discontinue immediately if any of the following occur: jaundice, visual problems (may cause contact lens intolerance), any signs of VTE, migraine with unusual severity, significant increase in BP, severe depression, increased risk of thromboembolic complications after surgery

            Discontinue therapy 4 weeks before major surgery or prolonged immobilization; may resume 2 weeks afterwards

            Monitor patients on oral anticoagulants (eg, warfarin); increased anticoagulant dose may be warranted due to thromboembolic risk with oral contraceptives

            Studies have shown an increased risk of cervical cancer with OCP use; however, HPV remains the main risk factor for cervical cancer; evidence suggests long-term use of OCPs (≥5 yr) may be associated with increased risk

            Studies have shown a significantly decreased endometrial cancer risk with OCP use; protective effect increases with longer duration of OCP use and may continue to persist years after OCP discontinuation

            Risk of ovarian cancer may decrease with increasing duration of OCP use

            Discontinue hormonal therapy prior to starting therapy with combination drug regimen ombitasvir/paritaprevir/ritonavir, with or without dasabuvir; may restart approximately 2 weeks following completion of treatment with combination drug regimen

            Increased risk of liver cancer with OCP use; risk increases with longer duration of OCP use

            Monitor prediabetic and diabetic women with dyslipidemias

            Breast cancer

            • Epidemiology studies have not found a consistent association between use of combined oral contraceptives (COCs) and breast cancer risk; studies do not show an association between ever (current or past) use of COCs and risk of breast cancer
            • Some studies report a small increase in risk of breast cancer among current or recent users(<6 months since last use) and current users with longer duration of COC use
            • A woman's risk depends on conditions where naturally high hormone levels persist for long periods of time including early-onset

            Thromboembolic disorders

            • Discontinue immediately if thrombotic event occurs
            • Risk of VTE is highest during the first year of use; interim data from a large, prospective cohort safety study of various combined oral contraceptives (COCs) suggest that this increased risk, as compared with that in non-COC users, is greatest during the first 6 months of COC use
            • Women taking drospirenone-containing contraceptives may have up to a 3-fold increased risk for developing VTE compared with women taking other combined hormonal contraceptives
            • To decrease risk of VTE events, CDC guidelines recommend waiting at least 3 weeks following vaginal birth or 6 weeks after cesarean section before initiating use of combined hormonal contraceptives; women with additional risk factors for VTE (besides postpartum) should not use combined hormonal contraceptives
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            There is no use for contraception in pregnancy; this medication should be discontinued during pregnancy; epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to CHCs before conception or during early pregnancy

            Lactation

            The drug is present in human milk; after a single oral administration of 3 mg DRSP/0.03 mg EE tablets, DRSP concentration in breast milk over the 24-h period ranged from 1.4 to 7.0 ng/mL, with a mean ± standard deviation value of 3.7 ± 1.9 ng/mL; estimated mean infant dose was 0.003 mg/day, which is about 0.1% of maternal dose; there is limited information on effects of this drug on breast-fed infant

            CHCs can reduce milk production in breastfeeding females; this reduction can occur at any time but is less likely to occur once breastfeeding is well-established; when possible, advise nursing female to use other methods of contraception until she discontinues breast-feeding

            Developmental and health benefits of breastfeeding should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed child from therapy or from underlying maternal condition

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            COCs lower the risk of becoming pregnant primarily by suppressing ovulation; other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation

            Absorption

            Bioavailability: 76% (drospirenone); 40% (ethinyl estradiol)

            Peak plasma time: 1-2 hr

            Peak plasma concentration: 88 ng/mL (drospirenone); 99 pg/mL (ethinyl estradiol)

            AUC: 830-970 ng.hr/mL (drospirenone); 350-470 pg.hr/mL (ethinyl estradiol)

            Distribution

            Protein bound

            • Ethinyl estradiol: >98% bound to serum albumin
            • Drospirenone: 97% bound to serum proteins (not SHBG or corticosteroid-binding globulin)

            Metabolism

            Hepatic metabolism

            Metabolites: Two acid forms of DSRP (inactive)

            Elimination

            Half-life: 24 hr (ethinyl estradiol); 30 hr (drospirenone)

            Excretion: Urine (38-47% as inactive metabolites), feces (17-20% as inactive metabolites)

            Previous
            Next:

            Images

            No images available for this drug.
            Previous
            Next:

            Patient Handout

            A Patient Handout is not currently available for this monograph.
            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.